Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 37%
Sell 5%
Strong Sell 0%

Bulls say

Tempus AI is well-positioned in the healthcare technology space with its unique Tempus Platform that utilizes AI to make laboratory tests more accurate and personalized. The recent FDA clearance for its ECG-PH software adds to its growing portfolio of FDA-cleared products, increasing its addressable market and reinforcing the scalability of its AI platform. With a projected sales per share of $9.87 and a net debt of $3.00 per share, we have a positive outlook for the company with a 12-month price target of $76. Risks to our outlook include lower than projected sales growth and potential dilution risk, but we believe the company's acquisition of Personalis and its role in individualized mRNA therapies, as well as its expansion into MRD coverage and data licensing, position it for strong growth and potential future partnerships.

Bears say

Tempus AI is acquiring Personalis, a move that is expected to improve the quality of the asset without changing the agreed upon consideration. With a mechanical proforma LTM EV/Revenue multiple of 8.9x, or 7.0x forward EV/Revenue multiple, and potential for premium due to successful integration, MRD adoption, and increased biopharma demand, the update is viewed as strategically positive. However, there may be reimbursement risks with Medicare coverage not guaranteeing commercial payer follow-on.

TEM has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 37% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 19 analysts, TEM has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.